Literature DB >> 16363886

Overcoming gaps in the management of asthma in older patients: new insights.

Pranoy Barua1, M Sinead O'Mahony.   

Abstract

Asthma is under-recognised and undertreated in older populations. This is not surprising, given that one-third of older people experience significant breathlessness. The differential diagnosis commonly includes asthma, chronic obstructive pulmonary disease (COPD), heart failure, malignancy, aspiration and infections. Because symptoms and signs of several cardiorespiratory diseases are nonspecific in older people and diseases commonly co-exist, investigations are important. A simple strategy for the investigation of breathlessness in older people should include a full blood count, chest radiograph, ECG, peak flow diary and/or spirometry with reversibility as a minimum. If there are major abnormalities on the ECG, an echocardiogram should also be performed. Diurnal variability in peak flow readings >or=20% or >or=15% reversibility in forced expiratory volume in 1 second, spontaneously or with treatment, support a diagnosis of asthma. Distinguishing asthma from COPD is important to allow appropriate management of disease based on aetiology, accurate prediction of treatment response, correct prognosis and appropriate management of the chest condition and co-morbidities. The two conditions are usually readily differentiated by clinical features, particularly age at onset, variability of symptoms and nocturnal symptoms in asthma, supported by the results of reversibility testing. Full lung function tests may not necessarily help in differentiating the two entities, although gas transfer factor is characteristically reduced in COPD and usually normal or high in asthma. Methacholine challenge tests previously mainly used in research are now also used widely and safely to confirm asthma in clinical settings. Interest in exhaled nitric oxide as a biomarker of airways inflammation is increasing as a noninvasive tool in the diagnosis and monitoring of asthma. Regular inhaled corticosteroids (ICS) are the mainstay of treatment of asthma. Even in mild disease in older adults, regular preventive treatment should be considered, given the poor perception of bronchoconstriction by older asthmatic patients. If symptoms persist despite ICS, addition of long-acting beta(2)-adrenoceptor agonists (LABA) should be considered. Addition of LABA to ICS improves asthma control and allows reduction in ICS dose. However, older people have been grossly under-represented in trials of LABA, many trials having excluded those >or=65 years of age. On meta-analysis, beta(2)-adrenoceptor agonists (both short acting and long acting) are associated with increased cardiovascular mortality and morbidity in asthma and COPD. While the evidence for excess cardiovascular mortality is stronger for short-acting beta(2)-adrenoceptor agonists, it would be prudent to exercise particular care in using beta(2)-adrenoceptor agonists (long acting and short acting) in those at risk of adverse cardiovascular outcomes, including older people. Regular review of cardiovascular status (and monitoring of serum potassium concentration) in patients taking beta(2)-adrenoceptor agonists is crucial. The response to LABA should be carefully monitored and alternative 'add-on' therapy such as leukotriene receptor antagonists (LRA) should be considered. LRA have fewer adverse effects and in individual cases may be more effective and appropriate than LABA. Long-term trials evaluating beta(2)-adrenoceptor agonists and other bronchodilator strategies are needed particularly in the elderly and in patients with cardiovascular co-morbidities. There is no evidence that addition of anticholinergics improves control of asthma further, although the role of long-acting anticholinergics in the prevention of disease progression is currently being researched. Older patients need to be taught good inhaler technique to improve delivery of medications to lungs, minimise adverse effects and reduce the need for oral corticosteroids. Nurse-led education programmes that include a written asthma self-management plan have the potential to improve outcomes.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16363886     DOI: 10.2165/00002512-200522120-00004

Source DB:  PubMed          Journal:  Drugs Aging        ISSN: 1170-229X            Impact factor:   3.923


  241 in total

1.  Increased bronchial hyperresponsiveness after inhaling salbutamol during 1 year is not caused by subsensitization to salbutamol.

Authors:  C P van Schayck; S J Graafsma; M B Visch; E Dompeling; C van Weel; C L van Herwaarden
Journal:  J Allergy Clin Immunol       Date:  1990-11       Impact factor: 10.793

2.  Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial.

Authors:  P S Burge; P M Calverley; P W Jones; S Spencer; J A Anderson; T K Maslen
Journal:  BMJ       Date:  2000-05-13

Review 3.  Inhaled and nasal corticosteroids: factors affecting the risks of systemic adverse effects.

Authors:  A Cave; P Arlett; E Lee
Journal:  Pharmacol Ther       Date:  1999-09       Impact factor: 12.310

4.  A comparison of histamine, methacholine, and exercise airway reactivity in normal and asthmatic subjects.

Authors:  M Chatham; E R Bleecker; P L Smith; R R Rosenthal; P Mason; P S Norman
Journal:  Am Rev Respir Dis       Date:  1982-08

5.  Therapeutic value of antidepressants in asthma.

Authors:  G Krommydas; K I Gourgoulianis; K Karamitsos; K Krapis; E Kotrotsiou; P A Molyvdas
Journal:  Med Hypotheses       Date:  2005       Impact factor: 1.538

6.  Assessment of diurnal variability of peak expiratory flow in stable asthmatics.

Authors:  Ashutosh N Aggarwal; Dheeraj Gupta; Vijay Kumar; Surinder K Jindal
Journal:  J Asthma       Date:  2002-09       Impact factor: 2.515

Review 7.  Anti-leukotriene agents compared to inhaled corticosteroids in the management of recurrent and/or chronic asthma in adults and children.

Authors:  F M Ducharme; G C Hicks
Journal:  Cochrane Database Syst Rev       Date:  2002

8.  Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care.

Authors:  M R Cowie; A D Struthers; D A Wood; A J Coats; S G Thompson; P A Poole-Wilson; G C Sutton
Journal:  Lancet       Date:  1997-11-08       Impact factor: 79.321

Review 9.  Abnormalities of pulmonary function in congestive heart failure.

Authors:  P Faggiano
Journal:  Int J Cardiol       Date:  1994-03-15       Impact factor: 4.164

10.  Adverse reactions to influenza vaccine in elderly people: randomised double blind placebo controlled trial.

Authors:  T M Govaert; G J Dinant; K Aretz; N Masurel; M J Sprenger; J A Knottnerus
Journal:  BMJ       Date:  1993-10-16
View more
  17 in total

1.  Asthma mortality in Puerto Rico: 1980-2007.

Authors:  Jose Antonio Bartolomei-Díaz; Alejandro Amill-Rosario; Luz Claudio; Wanda Hernández
Journal:  J Asthma       Date:  2010-11-01       Impact factor: 2.515

2.  Antileukotriene Agents Versus Long-Acting Beta-Agonists in Older Adults with Persistent Asthma: A Comparison of Add-On Therapies.

Authors:  Shoroq M Altawalbeh; Carolyn T Thorpe; Janice C Zgibor; Sandra Kane-Gill; Yihuang Kang; Joshua M Thorpe
Journal:  J Am Geriatr Soc       Date:  2016-06-28       Impact factor: 5.562

Review 3.  Anticholinergics/antimuscarinic drugs in asthma.

Authors:  Xavier Soler; Joe Ramsdell
Journal:  Curr Allergy Asthma Rep       Date:  2014-12       Impact factor: 4.806

4.  Validation of The 30 Second Asthma Test as a measure of asthma control.

Authors:  Sara Ahmed; Pierre Ernst; Robyn Tamblyn; Neil Colman
Journal:  Can Respir J       Date:  2007-03       Impact factor: 2.409

Review 5.  Optimal management of asthma in elderly patients: strategies to improve adherence to recommended interventions.

Authors:  Dianne P Goeman; Jo A Douglass
Journal:  Drugs Aging       Date:  2007       Impact factor: 3.923

6.  Asthma in the elderly: Current understanding and future research needs--a report of a National Institute on Aging (NIA) workshop.

Authors:  Nicola A Hanania; Monroe J King; Sidney S Braman; Carol Saltoun; Robert A Wise; Paul Enright; Ann R Falsey; Sameer K Mathur; Joe W Ramsdell; Linda Rogers; David A Stempel; John J Lima; James E Fish; Sandra R Wilson; Cynthia Boyd; Kushang V Patel; Charles G Irvin; Barbara P Yawn; Ethan A Halm; Stephen I Wasserman; Mark F Sands; William B Ershler; Dennis K Ledford
Journal:  J Allergy Clin Immunol       Date:  2011-09       Impact factor: 10.793

7.  Asthma in the Elderly: Can We Distinguish It from COPD?

Authors:  Eleni G Tzortzaki; Athanasia Proklou; Nikolaos M Siafakas
Journal:  J Allergy (Cairo)       Date:  2011-06-30

8.  Allergic diseases in the elderly.

Authors:  Victoria Cardona; Mar Guilarte; Olga Luengo; Moises Labrador-Horrillo; Anna Sala-Cunill; Teresa Garriga
Journal:  Clin Transl Allergy       Date:  2011-10-17       Impact factor: 5.871

9.  Asthma Control and Its Relationship with Obstructive Sleep Apnea (OSA) in Older Adults.

Authors:  Mihaela Teodorescu; David A Polomis; Ronald E Gangnon; Jessica E Fedie; Flavia B Consens; Ronald D Chervin; Mihai C Teodorescu
Journal:  Sleep Disord       Date:  2013-11-06

10.  'Get Your Life Back': process and impact evaluation of an asthma social marketing campaign targeting older adults.

Authors:  Uwana Evers; Sandra C Jones; Don Iverson; Peter Caputi
Journal:  BMC Public Health       Date:  2013-08-15       Impact factor: 3.295

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.